Added value for patients. For the diagnosis of high-grade lymphoma, a tissue biopsy currently remains the gold standard, but 
Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) (the most common types) often affect organs that are 
difficult to reach. In addition, the differential diagnosis usually includes a wide range of malignant and non-malignant 
conditions, which makes that patients would greatly benefit from a non-invasive test. Beyond diagnosis, a liquid biopsy that 
provides molecular information predictive of tumor aggressiveness/sensitivity to therapy would be highly advantageous in 
assisting the personalized management of the patient. Especially also in the monitoring of patients that achieve remission 
after treatment, such non-invasive test is needed for early-warning of imminent relapse, to be able to dispose of sufficient 
time to prepare personalized therapy in an era that will see advanced (cellular) immunotherapies gradually coming into play 
as second-line treatments after relaps